Role of DPR in Colorectal Cancer

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 9)
Volume 1
Issue 9

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Articles in this issue
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Role of DPR in Colorectal Cancer
Role of DPR in Colorectal Cancer
Overview of the Lume 1 and 2 Trials
Overview of the Lume 1 and 2 Trials
Impact of HER2 Amplification in Colorectal Cancer
Impact of HER2 Amplification in Colorectal Cancer
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
Novel Immunotherapy Combinations on Horizon for mCRC
Novel Immunotherapy Combinations on Horizon for mCRC
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Tim Cortese
May 21st 2025
Article

Oral selinexor as maintenance therapy extended progression-free survival in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)

Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)

Targeted Oncology Staff
May 19th 2025
Article

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Tony Berberabe, MPH
May 16th 2025
Article

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.

Read More

FDA Approves Retifanlimab, First Frontline Treatment for Advanced SCAC

FDA Approves Retifanlimab, First Frontline Treatment for Advanced SCAC

Sabrina Serani
May 15th 2025
Article

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of advanced anal cancer.

Read More